Censeo
Commercial- Indications
- Major depressive disorder, Bipolar disorder, Anxiety disorders, Schizophrenia, Autism spectrum condition
Company intelligence / Profile preview
Psyomics has developed and commercialized "Censeo," an AI-informed digital triage and assessment tool for mental health, used by clinicians to improve accuracy, speed, and patient engagement. The company is also developing combined digital and blood biomarker tests for early diagnosis of major psychiatric disorders. Clinical results focus on improved triage efficiency, reduced misallocation of patients on waiting lists, and enhanced decision support for clinicians.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Psyomics.